nodes	percent_of_prediction	percent_of_DWPC	metapath
Sulfacetamide—Secondary infection—Epirubicin—testicular cancer	0.0406	0.0406	CcSEcCtD
Sulfacetamide—Secondary infection—Doxorubicin—testicular cancer	0.0376	0.0376	CcSEcCtD
Sulfacetamide—Infection—Carboplatin—testicular cancer	0.0281	0.0281	CcSEcCtD
Sulfacetamide—Aplastic anaemia—Dactinomycin—testicular cancer	0.0276	0.0276	CcSEcCtD
Sulfacetamide—Toxic epidermal necrolysis—Chlorambucil—testicular cancer	0.0266	0.0266	CcSEcCtD
Sulfacetamide—Pain—Carboplatin—testicular cancer	0.0242	0.0242	CcSEcCtD
Sulfacetamide—Stevens-Johnson syndrome—Chlorambucil—testicular cancer	0.0226	0.0226	CcSEcCtD
Sulfacetamide—Agranulocytosis—Vinblastine—testicular cancer	0.0195	0.0195	CcSEcCtD
Sulfacetamide—Erythema multiforme—Chlorambucil—testicular cancer	0.0193	0.0193	CcSEcCtD
Sulfacetamide—Toxic epidermal necrolysis—Dactinomycin—testicular cancer	0.0192	0.0192	CcSEcCtD
Sulfacetamide—Toxic epidermal necrolysis—Ifosfamide—testicular cancer	0.0176	0.0176	CcSEcCtD
Sulfacetamide—Blister—Epirubicin—testicular cancer	0.0166	0.0166	CcSEcCtD
Sulfacetamide—Stevens-Johnson syndrome—Dactinomycin—testicular cancer	0.0163	0.0163	CcSEcCtD
Sulfacetamide—Agranulocytosis—Dactinomycin—testicular cancer	0.0154	0.0154	CcSEcCtD
Sulfacetamide—Blister—Doxorubicin—testicular cancer	0.0153	0.0153	CcSEcCtD
Sulfacetamide—Stevens-Johnson syndrome—Ifosfamide—testicular cancer	0.0149	0.0149	CcSEcCtD
Sulfacetamide—Stinging—Epirubicin—testicular cancer	0.0147	0.0147	CcSEcCtD
Sulfacetamide—Infection—Chlorambucil—testicular cancer	0.0144	0.0144	CcSEcCtD
Sulfacetamide—Blood disorder—Epirubicin—testicular cancer	0.0143	0.0143	CcSEcCtD
Sulfacetamide—Agranulocytosis—Ifosfamide—testicular cancer	0.0141	0.0141	CcSEcCtD
Sulfacetamide—Erythema multiforme—Dactinomycin—testicular cancer	0.014	0.014	CcSEcCtD
Sulfacetamide—Toxic epidermal necrolysis—Etoposide—testicular cancer	0.0139	0.0139	CcSEcCtD
Sulfacetamide—Erythema—Bleomycin—testicular cancer	0.0138	0.0138	CcSEcCtD
Sulfacetamide—Stinging—Doxorubicin—testicular cancer	0.0136	0.0136	CcSEcCtD
Sulfacetamide—Blood disorder—Doxorubicin—testicular cancer	0.0132	0.0132	CcSEcCtD
Sulfacetamide—Erythema—Dactinomycin—testicular cancer	0.0129	0.0129	CcSEcCtD
Sulfacetamide—Erythema multiforme—Ifosfamide—testicular cancer	0.0128	0.0128	CcSEcCtD
Sulfacetamide—Pain—Chlorambucil—testicular cancer	0.0124	0.0124	CcSEcCtD
Sulfacetamide—Aplastic anaemia—Methotrexate—testicular cancer	0.012	0.012	CcSEcCtD
Sulfacetamide—Stevens-Johnson syndrome—Etoposide—testicular cancer	0.0118	0.0118	CcSEcCtD
Sulfacetamide—Erythema—Ifosfamide—testicular cancer	0.0118	0.0118	CcSEcCtD
Sulfacetamide—Pain—Vinblastine—testicular cancer	0.0114	0.0114	CcSEcCtD
Sulfacetamide—Oedema—Bleomycin—testicular cancer	0.0112	0.0112	CcSEcCtD
Sulfacetamide—Aplastic anaemia—Epirubicin—testicular cancer	0.0112	0.0112	CcSEcCtD
Sulfacetamide—Infection—Bleomycin—testicular cancer	0.0112	0.0112	CcSEcCtD
Sulfacetamide—Agranulocytosis—Etoposide—testicular cancer	0.0111	0.0111	CcSEcCtD
Sulfacetamide—Hypersensitivity—Chlorambucil—testicular cancer	0.0107	0.0107	CcSEcCtD
Sulfacetamide—Oedema—Dactinomycin—testicular cancer	0.0105	0.0105	CcSEcCtD
Sulfacetamide—Infection—Dactinomycin—testicular cancer	0.0104	0.0104	CcSEcCtD
Sulfacetamide—Aplastic anaemia—Doxorubicin—testicular cancer	0.0104	0.0104	CcSEcCtD
Sulfacetamide—Pruritus—Chlorambucil—testicular cancer	0.0103	0.0103	CcSEcCtD
Sulfacetamide—Erythema—Cisplatin—testicular cancer	0.0102	0.0102	CcSEcCtD
Sulfacetamide—Erythema multiforme—Etoposide—testicular cancer	0.0101	0.0101	CcSEcCtD
Sulfacetamide—Hypersensitivity—Vinblastine—testicular cancer	0.00981	0.00981	CcSEcCtD
Sulfacetamide—Pain—Bleomycin—testicular cancer	0.00962	0.00962	CcSEcCtD
Sulfacetamide—Oedema—Ifosfamide—testicular cancer	0.00961	0.00961	CcSEcCtD
Sulfacetamide—Infection—Ifosfamide—testicular cancer	0.00955	0.00955	CcSEcCtD
Sulfacetamide—Dermatitis bullous—Epirubicin—testicular cancer	0.00906	0.00906	CcSEcCtD
Sulfacetamide—Pain—Dactinomycin—testicular cancer	0.00897	0.00897	CcSEcCtD
Sulfacetamide—Dermatitis bullous—Doxorubicin—testicular cancer	0.00838	0.00838	CcSEcCtD
Sulfacetamide—Toxic epidermal necrolysis—Methotrexate—testicular cancer	0.00833	0.00833	CcSEcCtD
Sulfacetamide—Oedema—Cisplatin—testicular cancer	0.00829	0.00829	CcSEcCtD
Sulfacetamide—Hypersensitivity—Bleomycin—testicular cancer	0.00829	0.00829	CcSEcCtD
Sulfacetamide—Infection—Cisplatin—testicular cancer	0.00823	0.00823	CcSEcCtD
Sulfacetamide—Pain—Ifosfamide—testicular cancer	0.00822	0.00822	CcSEcCtD
Sulfacetamide—Pruritus—Bleomycin—testicular cancer	0.00796	0.00796	CcSEcCtD
Sulfacetamide—Toxic epidermal necrolysis—Epirubicin—testicular cancer	0.0078	0.0078	CcSEcCtD
Sulfacetamide—Hypersensitivity—Dactinomycin—testicular cancer	0.00773	0.00773	CcSEcCtD
Sulfacetamide—Infection—Etoposide—testicular cancer	0.00754	0.00754	CcSEcCtD
Sulfacetamide—Toxic epidermal necrolysis—Doxorubicin—testicular cancer	0.00722	0.00722	CcSEcCtD
Sulfacetamide—Pain—Cisplatin—testicular cancer	0.00709	0.00709	CcSEcCtD
Sulfacetamide—Hypersensitivity—Ifosfamide—testicular cancer	0.00708	0.00708	CcSEcCtD
Sulfacetamide—Stevens-Johnson syndrome—Methotrexate—testicular cancer	0.00707	0.00707	CcSEcCtD
Sulfacetamide—Pruritus—Ifosfamide—testicular cancer	0.0068	0.0068	CcSEcCtD
Sulfacetamide—Agranulocytosis—Methotrexate—testicular cancer	0.00665	0.00665	CcSEcCtD
Sulfacetamide—Stevens-Johnson syndrome—Epirubicin—testicular cancer	0.00662	0.00662	CcSEcCtD
Sulfacetamide—Pain—Etoposide—testicular cancer	0.00649	0.00649	CcSEcCtD
Sulfacetamide—Agranulocytosis—Epirubicin—testicular cancer	0.00623	0.00623	CcSEcCtD
Sulfacetamide—Stevens-Johnson syndrome—Doxorubicin—testicular cancer	0.00612	0.00612	CcSEcCtD
Sulfacetamide—Hypersensitivity—Cisplatin—testicular cancer	0.00611	0.00611	CcSEcCtD
Sulfacetamide—Erythema multiforme—Methotrexate—testicular cancer	0.00605	0.00605	CcSEcCtD
Sulfacetamide—Agranulocytosis—Doxorubicin—testicular cancer	0.00576	0.00576	CcSEcCtD
Sulfacetamide—Erythema multiforme—Epirubicin—testicular cancer	0.00566	0.00566	CcSEcCtD
Sulfacetamide—Hypersensitivity—Etoposide—testicular cancer	0.00559	0.00559	CcSEcCtD
Sulfacetamide—Erythema—Methotrexate—testicular cancer	0.00557	0.00557	CcSEcCtD
Sulfacetamide—Pruritus—Etoposide—testicular cancer	0.00537	0.00537	CcSEcCtD
Sulfacetamide—Erythema multiforme—Doxorubicin—testicular cancer	0.00524	0.00524	CcSEcCtD
Sulfacetamide—Erythema—Epirubicin—testicular cancer	0.00522	0.00522	CcSEcCtD
Sulfacetamide—Erythema—Doxorubicin—testicular cancer	0.00483	0.00483	CcSEcCtD
Sulfacetamide—Infection—Methotrexate—testicular cancer	0.00452	0.00452	CcSEcCtD
Sulfacetamide—Oedema—Epirubicin—testicular cancer	0.00426	0.00426	CcSEcCtD
Sulfacetamide—Infection—Epirubicin—testicular cancer	0.00423	0.00423	CcSEcCtD
Sulfacetamide—Oedema—Doxorubicin—testicular cancer	0.00394	0.00394	CcSEcCtD
Sulfacetamide—Infection—Doxorubicin—testicular cancer	0.00391	0.00391	CcSEcCtD
Sulfacetamide—Pain—Methotrexate—testicular cancer	0.00389	0.00389	CcSEcCtD
Sulfacetamide—Pain—Epirubicin—testicular cancer	0.00364	0.00364	CcSEcCtD
Sulfacetamide—Pain—Doxorubicin—testicular cancer	0.00337	0.00337	CcSEcCtD
Sulfacetamide—Hypersensitivity—Methotrexate—testicular cancer	0.00335	0.00335	CcSEcCtD
Sulfacetamide—Pruritus—Methotrexate—testicular cancer	0.00322	0.00322	CcSEcCtD
Sulfacetamide—Hypersensitivity—Epirubicin—testicular cancer	0.00314	0.00314	CcSEcCtD
Sulfacetamide—Pruritus—Epirubicin—testicular cancer	0.00301	0.00301	CcSEcCtD
Sulfacetamide—Hypersensitivity—Doxorubicin—testicular cancer	0.0029	0.0029	CcSEcCtD
Sulfacetamide—Pruritus—Doxorubicin—testicular cancer	0.00279	0.00279	CcSEcCtD
